Summary We evaluated the MDR1 expression levels in 77 osteosarcomas and investigated whether MDR1 mRNA expression in osteosarcomas varies with location within the tumour, following chemotherapy, or after metastasis. We modified the semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) assay to determine accurately the levels of MDR1 mRNA expression in clinical specimens. We show that specimens collected from multiple locations in six tumours revealed very little variation in MDR1 expression suggesting that the levels of MDR1 in these tumours do not vary greatly with location within the tumour mass. In a comparison of pre and post-chemotherapy specimens it was found that MDR1 levels did not change appreciably following chemotherapy in 16 of 20 cases. In addition, in eight of ten specimens obtained before and after metastasis, the amount of MDR1 mRNA was found to remain relatively constant despite metastatic spread. Thus, many osteosarcomas exhibited intrinsic expression of MDRI mRNA before multidrug regimens which invariably included doxorubicin and, in most cases, MDR1 expression was not induced following chemotherapeutic treatment. Our results suggest that some osteosarcoma patients may have primary tumours which are resistant to doxorubicin. These individuals may benefit from different chemotherapeutic regimens, e.g. the addition of MDR reversal agents.
In vitro, the multidrug resistance phenotype is mediated by the expression of several genes, one of which is the 170 kDa P-glycoprotein efflux pump, which acts to decrease intracellular concentration of drugs. P-glycoprotein is encoded by the MDR] gene in humans and transfection of MDR1 cDNA confers resistance to a wide spectrum of anti-cancer drugs in vitro, including vinca alkaloids and anthracyclins (reviewed in Endicott and Ling, 1989; Borst, 1991; Gottesman and Pastan, 1993) . P-glycoprotein/MDRI expression is likely to be involved in the resistance of certain types of tumours, particularly leukaemias (Marie et al., 1993; Campos et al., 1992) and lymphomas (Miller et al., 1991) , to chemotherapy. Although the role of MDR1 in most solid tumours remains controversial, a correlation of P-glycoprotein expression and outcome has been demonstrated for some childhood cancers (Chen et al., 1991 (Chen et al., , 1990 . In addition, in a pilot study of osteosarcoma, we found that patients whose tumours expressed high levels of MDR1 mRNA tended to have a worse prognosis than those patients with low levels of tumour MDR1 expression (Wunder et al., 1993) . Doxorubicin, a drug involved in the MDR phenotype, is highly effective in the treatment of this disease and is included in all osteosarcoma chemotherapy protocols. Relapse in osteosarcoma patients could relate to the development of resistance to doxorubicin (Bell et al., 1990 ).
Numerous studies have described the detection of MDR1 or P-glycoprotein in a variety of cancers (Chan et al., 1990; Wunder et al., 1993; Goldstein et al., 1989; Holzmayer et al., 1992) ; however, methods traditionally used to measure levels of MDR1/P-glycoprotein expression in tumours demonstrated definite limitations. RNA hybridisation assays and immunohistochemistry are useful in detecting MDR1/Pglycoprotein overexpression but lack sensitivity to detect the lower levels of MDR1 expression known to confer drug resistance in cell lines (Shen et al., 1986) . Furthermore, there is evidence to suggest that low levels of expression may be clinically significant in tumours (Vergier et al., 1993) . In the present study we describe a refined RT-PCR assay capable of sensitive detection and quantitation of low-level MDR1 expression in tumour specimens. We have used this assay to address the question of whether MDR1 expression varies with location within the tumour by determining the level of MDR1 mRNA expression in multiple specimens collected from different sites of the same primary tumour. It has been shown that MDR1 expression may be induced in cell lines following transient exposure to chemotherapeutic agents (Chaudhary and Roninson, 1993) . To investigate whether MDR1 levels in osteosarcoma specimens could be increased by chemotherapy, we analysed specimens collected from tumours both before and after chemotherapy. We also investigated whether MDR1 expression changes with progression by analysing specimens from biopsy through recurrence with metastasis.
Materials and methods
Cell lines and tumour specimens KB3-1 parental drug-sensitive and KB8 and KB8-5 drugresistance carcinoma cell lines were obtained from MM Gottesman (Akiyama et al., 1985) . KB8 represents the first step in selection from KB3-1 cells and exhibits 2-fold resistance to colchicine and a 6-to 10-fold increase in MDR1 mRNA. KB8-5 cells have 40-fold increased expression of MDR1 without gene amplification and are four times more resistant to colchicine than KB3-1 cells.
All osteosarcoma specimens were obtained from patients who presented free of metastatic disease. All patients received neoadjuvant chemotherapy using protocols that included doxorubicin. When possible, specimens were collected at both biopsy and resection, as well as from various locations within the tumour. Specimens were also collected from lung metastasis in the event of recurrent systemic disease. Specimens were obtained immediately after removal and flash-frozen in liquid nitrogen. Specimens were pulverised while frozen and total RNA was extracted by a standard guanidinium thiocyanate-caesium chloride gradient procedure (Sambrook et al., 1989) . Small specimens (< 100 mg) were extracted by the acid guanidinium -phenol procedure (Chomczynski and Sacchi, 1987) . Test extractions using both techniques on the same specimen yielded similar quality RNA and consistent PCR results (data not shown). The RNA yield was measured by the orcinol reaction (Lin and Schjeide, 1969 Noonan et al. (1990) . cDNA was synthesised using 200 ng total cellular RNA in 8 ,l of reverse transcriptase (RT) reaction solution. RT activity was denatured by incubation at 94°C for 5 min. PCR was performed using 4 ,l of the denatured cDNA reaction (100 ng) in a total 12 jul reaction volume containing 1 mM magnesium chloride, 10 mM Tris-HCl (pH 8.3), 50 mM potassium chloride, 0.01% gelatin, 0.2 units AmpliTaq Polymerase (Perkin-Elmer/Cetus) and 22.5 pmol of each primer. Parameters for amplification were an initial 4 min denaturation at 94°C, followed by 25 to 31 cycles of 30 s at 94°C, 30 s at 55°C, 1 min at 72°C (Thermocycler, PerkinElmer/Cetus). Primers specific for MDR1 were those described in Noonan et al. (1990) and generated at 167 bp product. These were co-amplified with porphobilinogen deaminase (PBGD)-specific primers 5'-TGTCTGGTAACG-GCAATGCG-3' (sense strand, exon 1) and 5'TTGCCAC-CACACTGTCCGTCT-3' (antisense strand, exon 3) which generated a 121 bp product (Finke et al., 1993) . PBGD served as an internal control for the quality and amount of template in each reaction. The MDR1 and PBGD primers were initially tested in separate reactions. Using the two sets of primers together in the same reaction did not alter the kinetics of amplification and therefore the products were coamplified. The PCR products were separated by 12% polyacylamide gel electrophoresis (PAGE), stained with ethidium bromide, photographed with positive/negative film (Polaroid) and the band intensities were quantitated by laser densitometry (Molecular Dynamics 300A computing Densitometer) from the negatives. For each sample, reactions were performed over a range of cycles (generally 25-31) which included the logarithmic phase of the PCR. Only values in the logarithmic phase (typically 25 to 27 cycles for 100 ng of cDNA) were used to quantitate the levels of mRNA expression. Each sample was assayed at least twice. The ratio of MDR1 mRNA was calculated relative to that of PBGD mRNA in each reaction. A reaction using KB8 RNA was included in each RT-PCR as a kinetic control. KB8 was also used as a standard of low level of functional expression against which tumour MDR1 expression was normalised.
Results
Quantitative assay for MDR] mRNA expression The semiquantitative RT-PCR assay of Noonan et al. (1990) was modified to quantitate the levels of MDR1 mRNA observed in osteosarcomas. Expression of the PBGD mRNA was used as an internal control owing to its low level of expression, and since it has been found to lack pseudogenes (Chretien et al., 1998) . A series of multidrug-resistant cell lines selected from KB3-1-sensitive cells were used to optimise the assay conditions and were subsequently used as controls in each experiment. Kinetic analysis of RT-PCR with the KB cell line RNAs using PBGD as an internal control gene is shown in Figure 1 . The KB8 cell line exhibited coincidence of the logarithmic phase of amplification of PBGD-specific product over a similar range of cycles as MDR1-specific product. Thus, the low level of expression of MDR1 mRNA
The level of expression of MDR1 mRNA was evaluated as shown in Figure 2 in 77 primary osteosarcomas and found to vary extensively among the different specimens (Figure 3) Figure 4 .
Comparison of MDR] mRNA levels before and after neoadjuvant chemotherapy For 20 cases, biopsy and resection specimens were collected before and after the administration of neoadjuvant chemotherapy, which included doxorubicin. The levels of expression found before and after administration of Figure 5) . The increases in expression in these four cases were 0.6 to 2.6 (case 6), 1.1 to 2.4 (case 10), 1.3 to 3.5 (case 12) and 2.8 to 7.3 (case 19). In the remaining 16 cases, seven showed somewhat higher levels of expression after chemotherapy and nine showed somewhat lower levels after drug treatment. None of the cases demonstrating a lower expression after chemotherapy fell more than 50% of the pretreatment level.
Evaluation of MDRI mRNA levels in metastatic lesions Specimens were obtained before and after metastasis for ten osteosarcoma patients. As indicated in Table II (sites 1 and 2) . Levels of MDR1 and internal control PBGD mRNAs were by RT -PCR analysis over four cycles (25 -31 cycles). Levels were determined from the logarithmic phase of the RT-PCR for each sample and values were calculated relative to the levels exhibited by KB8 cells as described in Materials and methods. (Noonan et al., 1990) . The issues of sensitivity (Kandel et al., 1995) as well as specificity of the antibodies (Rao et al., 1994 ) remain a major concern in the interpretation of these studies. Previous investigations in our laboratory have shown that commercially available antibodies to P-glycoprotein fail to allow reliable detection of protein in drug-resistant cell lines expressing at levels lower than KB8-5 (Kandel et al., 1995) . This method of detection, therefore, is not sufficiently sensitive to detect gene expression in the majority of clinical osteosarcoma specimens which express the gene in lower levels more similar to KB8 cells. In (Chaudhary and Roninson, 1993) . Induction of MDR1 mRNA was evaluated in the present study by determining expression levels before and after the administration of adjuvant multidrug regimes that invariably included doxorubicin. In four of 20 cases, the expression increased substantially, more than doubling. In the remaining 16 cases, the expression either increased somewhat or fell less than 50% following chemotherapy. These results suggest that in a minority of osteosarcoma, induction of mRNA may be increased to the point that resistance becomes a clinical concern. However, in the majority of cases, levels are not significantly altered by drug treatment.
Previous studies suggested an association of MDR1 expression with tumour metastasis (Weinstein et al., 1991) . If MDR1 is responsible for resistance leading to recurrence, MDR1 levels would be expected to increase in later stages either owing to the selection of MDR1-expressing cells by chemotherapy, or owing to a change in the phenotype of tumour cells. Contrary to these expectations, the majority of cases in this study were found to have relatively constant levels of MDR1 upon recurrence with metastasis to the lungs.
Many pretreatment tumours exhibited moderate levels of MDR1 expression suggesting that some osteosarcomas may be intrinsically drug resistant. Our data indicate that increased mRNA expression is rarely selected for by chemotherapy in osteosarcomas and that tumour progression does not necessarily involve overexpression of MDR1. In addition, it is possible that mechanisms other than MDR may play a role in the development of clinical chemoresistance observed in osteosarcomas. Studies on the effects of MDR1 expression on patient outcome are required to test the clinical significance of MDR1 expression in osteosarcoma further and these investigations are in progress.
